课题基金 / 基金详情

Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis

Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis
通过 IL23-IL17 轴靶向免疫炎症途径治疗子宫内膜异位症
批准号:
356264
负责人:
Tayade Chandrakant
金额:
$45.14万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-10-01 至 2021-10-01

项目摘要

项目成果

Tayade Chandrakant的其他基金

相似基金

相关文献

中文摘要
翻译
子宫内膜异位症是子宫切除、不孕不育和盆腔疼痛的最常见原因,其特征是子宫内膜衬里在子宫外生长。它影响6-10%的育龄妇女和35-50%有盆腔疼痛/不明原因的妇女
英文摘要
Endometriosis, characterized by growth of endometrial lining outside of the uterus, is the most prevalent global cause for hysterectomy, infertility and pelvic pain. It affects 6-10% of reproductive age women and 35-50% in women with pelvic pain/unexplain
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unique extracellular vesicle signatures in the pathophysiology of endometriosis
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting.
Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality.
海外基金